This article is more than 5 years old. Information may no longer be current.
No link between nosocomial C. difficile recurrence, concurrent PPI use/infection treatment
Click Here to Manage Email Alerts
Hospitalized patients with Clostridium difficile infection were not at increased risk for recurrence when treated with proton pump inhibitors concurrently with infection therapy in a recent study.
Researchers evaluated data from 894 adult patients who developed incident C. difficile infection (CDI) while hospitalized between Dec. 1, 2009 and June 30, 2012. Recurrence was defined as a positive stool test within 15 to 90 days of the initial diagnostic test. Proton pump inhibitors (PPI) administered in-hospital along with CDI treatment was defined as the primary exposure.
Participants received concurrent PPI and CDI treatment in 62% of cases, and recurrence occurred in 23% of the cohort. Patients receiving PPI therapy were more likely to be receiving antibiotics (86% of cases vs. 52%) and immunosuppressants (47% vs. 15%) and require an ICU stay (53% vs. 27%), and had longer hospital stays (median, 17 days vs. 8 days) than nonrecipients (P<.01 for all). Ninety-day mortality was more common among patients who experienced recurrence (32% vs. 25%; P=.03).
Factors associated with recurrence on multivariate analysis included advanced age (HR=1.02; 95% CI, 1.01-1.03 per year), more comorbidities (HR=1.09; 95% CI, 1.04-1.14 per point on the Charlson comorbidity index) and black race (HR=1.66; 95% CI, 1.05-2.63). No association was observed between infection recurrence and concurrent PPI/CDI therapy (HR=0.82; 95% CI, 0.58-1.16), or between increased dose or duration of PPI treatment.
Sensitivity analysis in a subgroup of 635 patients who survived a 90-day follow-up period after initially testing positive for CDI indicated no association between PPI use and CDI recurrence (HR=0.87; 95% CI, 0.6-1.28).
“Our primary results are best applied to populations that resemble the patients in our study — patients in tertiary care settings with a high degree of illness and multiple comorbidities,” the researchers wrote. “Although hospitalized patients frequently receive PPIs without indication, in-hospital administration of PPIs does not increase the risk of CDI recurrence. Future studies should test interventions to prevent CDI recurrence among high-risk inpatients.”
Disclosure: Researcher Carol Friedman, PhD, serves as a consultant for a company that licenses the MedLEE natural language processing system.
Click Here to Manage Email Alerts